Law360, Washington (October 05, 2011, 4:27 PM ET) -- A slew of generic-drug companies defending against AstraZeneca PLC’s multidistrict infringement litigation over Crestor told the Federal Circuit on Wednesday that a patent for the cholesterol drug is invalid because the patentees omitted prior art references in the application.
The eight generics makers are appealing a Delaware federal judge’s June 2010 decision that they failed to establish that U.S. Patent Number RE37,314, which covers Crestor's active ingredient rosuvastatin, is unenforceable due to inequitable conduct. They also failed to establish the patent was invalid as obvious or...
Generics Cos. Rip AstraZeneca’s Crestor IP In Fed. Circ.
To view the full article, take a free trial now.
